Method for obtaining crystallized fetal bovine serum containing agmatine
The crystallization of fetal bovine serum using agmatine addresses storage and contamination issues, enhancing cell culture efficiency and reproducibility by allowing room temperature storage and maintaining formulation integrity.
JP2026520903APending Publication Date: 2026-06-25モエダノ ララ ラウル フランシスコ
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025570177
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-04-08
- Publication Date
- 2026-06-25
AI Technical Summary
Technical Problem
Current fetal bovine serum formulations require cold chain storage, leading to batch-to-batch variability, contamination risks, and high costs, limiting reproducibility and efficiency in cell culture applications.
Method used
A method for crystallizing fetal bovine serum using agmatine, which allows for storage at room temperature, reduces contamination, and maintains formulation integrity, enabling efficient dosage setting and distribution.
Benefits of technology
The crystallized fetal bovine serum maintains properties similar to liquid serum, enhances cell proliferation and protein expression, and reduces contamination risks, improving reproducibility and cost-effectiveness in cell culture.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a method for obtaining crystallized fetal bovine serum by adding agmatine, which has the effect of increasing cell production and increasing protein expression per cell at a specific concentration. Furthermore, the method, with respect to a specific reconstitution form into a liquid, is shown for use without losing its original properties, allowing for storage without a cryogenic chain, reducing the risk of contamination, and enabling precise dosage.
Need to check novelty before this filing date? Find Prior Art